New mapping tech aims to stop AFib in its tracks

NCT ID NCT07358611

First seen Jun 25, 2026 · Last updated Jul 09, 2026 · Updated 3 times

Summary

This pilot study tests whether using a noninvasive global mapping system to guide catheter ablation can improve outcomes for people with persistent atrial fibrillation. Thirty participants will receive standard pulmonary vein isolation plus personalized ablation of up to three additional heart regions identified by the mapping system. Researchers will track how often the heart returns to normal rhythm during the procedure and how many patients remain free of arrhythmia for a year.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
catheter ablation guided by noninvasive global mapping
What this could lead to
If successful, this personalized ablation approach could reduce the chance of atrial fibrillation coming back after treatment.
What could go wrong
This is a small pilot study with only 30 participants, so results may not apply to everyone. The procedure carries standard risks of catheter ablation, such as bleeding or heart rhythm issues.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ATRIAL FIBRILLATION (AF) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Hospital Clinic, University of Barcelona

    RECRUITING

    Barcelona, 08036, Spain

More trials for these conditions

Other studies related to the condition(s) this trial covers.